Bivamelagon

Human clinical Weight Loss & Metabolism 2 sources

Bivamelagon is an investigational oral small-molecule melanocortin-4 receptor (MC4R) agonist. Research shows it can significantly reduce body mass index (BMI) and improve hunger control in patients with acquired hypothalamic obesity.

01Dosing reference

Amount

400mg to 600mg

Frequency

Once daily

Cycle

Continuous daily use as studied in clinical trials

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

MC4R Activation

Bivamelagon binds to and activates the melanocortin-4 receptor (MC4R) in the hypothalamus.

Appetite and Energy Regulation

Activation of MC4R signals the brain to reduce hunger and increase energy expenditure.

Weight Management

This mechanism helps patients with hypothalamic obesity achieve significant BMI reductions and better appetite control.

03Human evidence

Statistically significant BMI reductions of 9.3% and 7.7% in 600mg and 400mg cohorts, respectively.

Phase 2 double-blind, placebo-controlled trial in patients with acquired hypothalamic obesity.

Improved hunger control and weight management over extended periods.

Long-term open-label extension studies evaluating safety and tolerability over up to 2 years.

04Preclinical evidence

Exhibits weight-loss properties and regulates energy homeostasis.

Animal models of obesity and diabetes.

Potential utility in studying inflammation and erectile dysfunction.

In vitro and in vivo preclinical assays evaluating MC4R agonism.

05What is known vs. unknown

Reasonably established

Bivamelagon is an oral MC4R agonist, offering a non-injectable alternative for targeting this pathway.
It has shown significant efficacy in reducing BMI in patients with acquired hypothalamic obesity.
The compound is currently in Phase 2 and long-term extension clinical trials.
It is being developed by Rhythm Pharmaceuticals for specific obesity indications.

Unknowns & limits

Long-term safety and tolerability over multiple years are still being evaluated in ongoing extension studies.
Its efficacy in broader, non-hypothalamic obesity populations remains to be fully established.

06Safety & regulatory context

Regulatory statusBivamelagon is an investigational drug and is not FDA-approved. It is currently being evaluated in clinical trials for hypothalamic obesity. While early Phase 2 data suggests it is generally well-tolerated, long-term safety data is still being collected. Potential side effects associated with MC4R agonists can include nausea, hyperpigmentation, and cardiovascular effects, though specific detailed safety profiles for Bivamelagon are pending full publication of trial results.

07Compared with Setmelanotide

Bivamelagon vs. Setmelanotide

Key difference

Setmelanotide is an injectable MC4R agonist approved for specific rare genetic obesities, whereas Bivamelagon is an oral small-molecule MC4R agonist.

When researchers discuss each

Setmelanotide is discussed as an established, FDA-approved injectable therapy for rare genetic obesities, while Bivamelagon is discussed as a promising oral alternative currently in trials for hypothalamic obesity.

08Glossary

Melanocortin-4 receptor (MC4R)

A receptor in the brain that plays a key role in regulating appetite and energy balance.

Hypothalamic obesity

A type of severe obesity caused by damage to the hypothalamus, often from tumors or surgery, disrupting hunger signals.

Agonist

A substance that binds to a receptor and activates it to produce a biological response.

09Knowledge check

Q1What is the primary mechanism of action for Bivamelagon?

Q2How is Bivamelagon administered?

Q3Which documented limitation of the Bivamelagon clinical evidence is stated in the dossier?

Q4According to the dossier, what is a key difference between Bivamelagon and setmelanotide?

Q5Which statement about Bivamelagon's regulatory status and safety profile is supported by the dossier?

10Sources

Journal Efficacy And Safety Of Once-daily Oral Bivamelagon In Acquired Hypothalamic Obesity
ClinicalTrials.gov A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.